Top Genome Editing Companies

The genome editing market will continue to grow because of the growing number of genetic disorders, chronic diseases, and cancers, leading to an increasing demand for more precise and effective therapeutics to treat these conditions. Rapid advancements in gene editing technologies, including CRISPR-Cas9, TALEN, and ZFN have provided researchers with increased access to and reduced costs for targeted gene editing, speeding up the pace at which gene editing technology can be implemented clinically as well as within the laboratory setting.

Industry Overview

According to SkyQuest Technology “Genome Editing Market By Technology ((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganucleases), By Delivery Mode (ex-Vivo, In-Vivo), By Application (Genetic Engineering, Clinical Applications), By Mode, By Region- Industry Forecast 2025-2032,” Global Genome Editing Market is projected to grow at a CAGR of over 16.8% by 2032, on account of urgent need for automating quantified data. An increasing number of applications within agriculture for using genome editing technology to increase crop yield and disease resistance as well as livestock genetics are driving further growth within this market.

Top 10 Global Genome Editing Companies

1. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific imports more types of different types of laboratory equipment than anyone else and has a very strong presence in selling products used in genetic engineering research and development.

2. Merck K.G.A. (MilliporeSigma)

Merck K.G.A. operates as MilliporeSigma in North America manufactures and sells lab supplies that are foundational to the life sciences industry and is an important supplier to labs worldwide.

3. CRISPR Therapeutics AG

Nobel Laureate Jennifer Doudna was an initial investor in CRISPR Therapeutics; CRISPR Therapeutics AG is focused on developing transformative therapies for mankind that allow the application of CRISPR technology for clinical applications. As part of this process, they have successfully completed the clinical trials of Casgevy (the first Food and Drug Administration approved CRISPR-based therapy) to treat sickle cell disease and beta-thalassemia, which represented significant milestones in their development efforts.

4. Intellia Therapeutics

Intellia Therapeutics is working to advance the use of CRISPR technology for therapeutic use and to enable its use as a technology to enable in vivo gene editing (i.e., CRISPR has been delivered directly to patients to edit specific genes in living cells). A key strategy for Intellia Therapeutics has been the development of lipid nanoparticles (LNPs) to deliver the biological material needed to apply CRISPR to the affected tissues.

5. Beam Therapeutics

Beam Therapeutics is pioneering Base Editing, a next-generation approach to content. Base editing is a modified version of CRISPR that adds a specific chemical alteration to a base (e.g. A-C) without creating a break in double-stranded DNA like traditional CRISPR (e.g. Cas9).

6. Precision BioSciences

Precision BioSciences has developed a proprietary gene-editing platform called ARCUS that uses meganucleases. ARCUS is marketed as the smaller and more versatile option compared to Cas9, producing precise gene insertions, deletions, and repairs.

7. Editas Medicine

Editas Medicine is a clinical-stage Biopharma, a pioneer in the CRISPR space, utilizing both Cas9 and Cas12 (formerly known as Cpf1) nucleases to target a wider variety of potential mutations.

8. GenScript

GenScript is a contract research organization (CRO), with world will help to develop research materials and provide related services and is in the U.S. and China. GenScript's role in the gene editing value ecosystem is to provide quality, custom-made gene synthesis and CRISPR reagents and to support the development of cell lines.

9. Cellectis

Cellectis is a French clinical-stage biotechnology company developing "off-the-shelf" CAR T-cell immunotherapies for cancer treatment using TALENs to modify T cells extracted from healthy donors. The use of TALENs allows for the development of off-the-shelf therapies with additional advantages over patient-specific therapies in terms of manufacturing simplification and wider availability.

10. Prime Medicine

Prime Medicine is focused solely on Prime Editing and is one of the first companies to utilize this exciting new technology. Prime Editing is viewed as the next evolution in gene editing, allowing for more precise control over gene sequences by providing the ability to perform a "search-and-replace" format.

Other Leading Global Genome Editing Companies

• Sangamo Therapeutics
• Caribou Biosciences
• Verve Therapeutics
• Mammoth Biosciences
• Vertex Pharmaceuticals
• Integrated DNA Technologies (IDT)
• Horizon Discovery
• Viatris
• Locus Biosciences
• Metagenomi
• uniQure

Conclusion

As advances in technology and funding for research continue to grow, the genome editing market is expected to experience rapid growth in its usage in various fields such as healthcare, agriculture and industrial biotechnology. By utilizing personalized medicine, gene therapy, and precision agriculture, genome editing has become a pivotal resource for solving unmet medical needs as well as increasing the overall availability of food security on a global level. As regulatory frameworks change to facilitate safe and ethical usage; this increases confidence in the market. Additionally, with continued maturation of technology we anticipate further collaborations among biotech companies, academic institutions, and healthcare providers which will further drive innovation, reduce costs and increase widespread adoption of genome editing solutions worldwide.